Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Toyonaka-city, Japan Clinical Trials

A listing of Toyonaka-city, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (38) clinical trials

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

The purpose of this study is to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in COPD patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple combination therapy of LABA, LAMA and ICS with …

Phase

1.27 miles

Learn More »

Efficacy and Safety Study of HLCM051(MultiStem ) for Pneumonic Acute Respiratory Distress Syndrome

The objectives of this clinical study are as follows(ARDS caused by pneumonia cohort): Primary objective To investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonia Secondary objective To confirm the safety of HLCM05 in patients with ARDS caused by pneumonia Exploratory objective To investigate changes of biomarkers …

Phase

3.05 miles

Learn More »

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

This study is a phase 2 multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of SP-02L monotherapy in relapsed or refractory patients with peripheral T-cell lymphoma.

Phase

3.07 miles

Learn More »

Study of NAC of GA Therapy for Patients With BRPC

Gemcitabine plus nub-paclitaxel (GA) regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer. GA is one of the high response rate treatment regimen, the investigators considered as a promising treatment as neoadjuvant chemotherapy. On the other hand, …

Phase

3.07 miles

Learn More »

A Study of TAK-994 in Participants With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 [NT1] or Narcolepsy Type 2 [NT2])

The drug being tested in this study is called TAK-994. The study will enroll up to approximately 126 participants. Participants will be randomly assigned (by chance, like flipping a coin) in 2:1 ratio to one of the 6 treatment Cohorts: Cohort 1, NT1 Participants: TAK-994 Dose Level 1 Cohort 2, …

Phase

3.44 miles

Learn More »

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).

Phase

4.06 miles

Learn More »

Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Non-alcoholic Steatohepatitis (NASH) and Stage 3 or Stage 4 Liver Fibrosis

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001 (100 mg, 200 mg and 400 mg PO QD), compared with placebo, in NASH subjects with Stage 3 and Stage 4 fibrosis. This study is designed to assess response …

Phase

4.06 miles

Learn More »

Study of Efficacy Safety Tolerability Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody CFZ533 in Kidney Transplant Recipients

The purpose of this study is to investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of three CFZ533 dose regimens in kidney transplant recipients. This study will allow assessment of the ability of CFZ533 to replace Calcineurin inhibitors (CNIs) in terms of anti-rejection efficacy, while providing better renal function …

Phase

4.09 miles

Learn More »

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Eligible patients will be treated with P1101, starting at 100 g (or 50 g in patients under another cytoreductive therapy). The dose should be gradually increased by 50 g every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilization of the hematological parameters is …

Phase

4.09 miles

Learn More »

Vincristine Dactinomycin and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma

OBJECTIVES: - Determine the progression-free survival rate in patients with low-risk embryonal rhadomyosarcoma treated with a shortened treatment schedule of vincristine, dactinomycin, and cyclophosphamide with or without radiotherapy. OUTLINE: Patients receive vincristine IV, dactinomycin IV, and cyclophosphamide IV. Patients may also undergo radiotherapy. Treatment repeats every 3 weeks for up …

Phase

4.09 miles

Learn More »